Approved indications: Locametz, after radiolabeling with gallium‑68, is FDA‑approved as a diagnostic agent for PET imaging of PSMA‑positive lesions in men with prostate cancer: (1) with suspected metastasis who are candidates for initial definitive therapy; (2) with suspected recurrence based on elevated PSA; and (3) to select patients with metastatic prostate cancer for whom PSMA‑directed therapy (such as lutetium Lu 177 vipivotide tetraxetan) is being considered.

Off‑label uses: Use outside these indications (for example, routine treatment‑response monitoring or use in non‑prostate tumors) is limited and considered off‑label; available data are mostly small studies or observational series, so evidence is weaker than for approved uses and practice is not standardized.

Efficacy expectations:

• Locametz PET/CT is typically performed 50 to 100 minutes after injection and provides same‑day images; it does not treat cancer but helps locate PSMA‑positive disease throughout the body.
• Clinical trials have shown high detection rates for both newly diagnosed higher‑risk disease and biochemical recurrence, often finding lesions that are missed by conventional imaging such as CT, bone scan, or standard MRI.
• Compared with older non‑PSMA tracers, PSMA‑targeted PET agents like Locametz generally offer greater sensitivity and clearer localization of prostate cancer lesions, which can improve staging, guide biopsy or surgery, and help select patients likely to benefit from PSMA‑directed radioligand therapy.

Typical dosing and how it is given: For adults, the recommended radioactivity is 111 to 259 MBq (3 to 7 mCi) of gallium Ga 68 gozetotide given as a single slow intravenous injection, usually followed by an IV saline flush. PET (often PET/CT) whole‑body imaging is then performed about 50 to 100 minutes after injection. No routine dose adjustment is needed for older patients or those with kidney or liver impairment, and the drug is not used in children.

Patient preparation and special instructions: Patients are typically asked to arrive well hydrated and to empty their bladder just before imaging, then to urinate frequently afterward to help reduce radiation to the bladder. A short‑acting diuretic may be given in some centers to enhance urinary excretion. Locametz is prepared and handled only by trained nuclear medicine staff; patients do not mix or store the medication themselves and should simply follow the imaging center’s instructions for arrival time, clothing, and removal of metal objects.

Missed dose and overdose: If a patient misses an appointment or injection time, the nuclear medicine department will usually reschedule the scan and prepare a new dose rather than "making up" a dose later. Overdose is unlikely because the tracer is prepared and measured under strict radiation‑safety controls; if excessive activity were administered, management would focus on increasing elimination (such as maintaining good hydration and frequent voiding) and supportive care while monitoring for any local injection‑site injury.

Common side effects: Locametz is usually well tolerated; in studies, the most frequent side effects were mild and short‑lived, including fatigue, nausea, constipation, and vomiting, each occurring in about 1% or less of patients. Some people may also experience diarrhea, dry mouth, chills, or minor injection‑site reactions such as warmth, bruising, or discomfort.

Serious or rare adverse effects: Serious reactions are rare; potential concerns include injection‑site extravasation (leakage of the tracer outside the vein) causing local irritation and the small added lifetime risk of cancer from radiation exposure. Any signs of a severe allergic‑type reaction (such as trouble breathing, widespread rash, or significant swelling) or severe pain, redness, or skin damage at the injection site require immediate medical attention.

Warnings and precautions: Because Locametz is a radiopharmaceutical, it contributes a low but measurable dose of ionizing radiation, so it is used only when the expected diagnostic benefit outweighs this risk. It is indicated for men with prostate cancer and is not intended for use in women or children; all radiopharmaceuticals could theoretically harm a fetus or nursing infant, so pregnancy and breastfeeding are generally avoided. No dose adjustment is typically needed for older adults or for kidney or liver impairment, but the kidneys and urinary bladder receive relatively higher radiation doses, so good hydration and frequent urination are encouraged.

Overall safety profile: Compared with many cancer drugs, Locametz has a favorable safety profile because it is given as a single low‑dose injection for imaging, with minimal systemic toxicity and primarily transient, mild side effects plus the inherent radiation risk.

Side‑effect reporting and safety updates: Patients should promptly tell their healthcare team about any unexpected or bothersome symptoms after the scan. Side effects can be reported in the United States through FDA MedWatch (online or at 1‑800‑FDA‑1088), and up‑to‑date safety and prescribing information is available from the product’s prescribing information and the FDA’s and manufacturer’s websites.

Drug and other interactions: No clinically important interactions with most prescription medicines, over‑the‑counter drugs, or supplements are known for Locametz, because it is used in very small amounts and cleared mainly through the kidneys. However, therapies that alter androgen signaling (such as androgen deprivation therapy or androgen‑receptor–targeting agents) can change PSMA expression and therefore affect how lesions appear on the scan, so the imaging physician should know about these treatments. Food and alcohol do not meaningfully interact with the tracer, though patients may be given specific instructions by the imaging center regarding eating or drinking before the scan.

Precautions and conditions requiring care: Because Locametz is a radioactive agent, its use is restricted to facilities licensed to handle radiopharmaceuticals, and it must be administered intravenously by trained staff to minimize extravasation and occupational exposure. Caution is advised in patients with markedly impaired kidney function, since clearance of the tracer may be slower and kidney radiation dose higher, and in anyone with a history of reactions to similar contrast or radiopharmaceutical agents. The drug is not indicated for women or pediatric patients; any potential use in these groups would require careful risk–benefit assessment due to radiation to the fetus, ovaries, or developing tissues.

Monitoring needs: Routine blood tests or ECGs are not usually required specifically for Locametz, but standard clinical monitoring (vital signs, assessment for allergic or injection‑site reactions) is performed around the time of administration. Interpretation of the PET images should be done by experienced nuclear medicine or radiology specialists, who will correlate findings with other imaging, laboratory results, and clinical history to avoid misinterpretation.

Q: What is Locametz and why has my doctor ordered it?
A: Locametz is a radioactive tracer used during a PET/CT scan to find prostate cancer cells that express a protein called PSMA, helping your care team see where prostate cancer may be present or has returned and to decide on the best treatment plan.

Q: What will happen on the day of my Locametz scan?
A: At the imaging center, you will have an IV line placed, receive a small injection of Locametz, wait quietly for about an hour while it circulates, then lie on the PET/CT scanner table for images; the injection itself is quick and the scan is painless, though you will need to stay fairly still.

Q: How long does Locametz stay in my body and is the radiation dangerous?
A: Locametz contains gallium‑68, which gives off radiation for a short time and then decays quickly; most of the radioactivity is gone within a day or so and is excreted in the urine, and while any radiation carries a small long‑term risk, the dose from a single scan is relatively low and is balanced against the benefit of accurate cancer imaging.

Q: Are there side effects I should watch for after the scan?
A: Most people feel well, but mild tiredness, nausea, constipation, or vomiting can occur; contact your healthcare team right away if you notice severe or worsening pain, marked redness or swelling at the injection site, trouble breathing, or any other unexpected severe symptoms.

Q: Can I have a Locametz scan if I am receiving hormone therapy or chemotherapy for prostate cancer?
A: Yes, many patients undergo Locametz PET/CT while on hormone therapy or other treatments, but these medicines can change how strongly lesions take up the tracer, so it is important to tell the imaging team exactly which cancer treatments you are receiving and when you last had them.